Abstract: The present invention provides methods for producing antibodies against a variety of antigens, including mammalian antigens with highly conserved epitopes. In addition, the present invention provides improved methods and compositions for the cloning and manipulation of immunoglobulin genes as well as antibodies derived therefrom.
Type:
Grant
Filed:
August 6, 1997
Date of Patent:
November 13, 2001
Assignee:
Arch Development Corporation
Inventors:
Nancy M. Michael, Mary Ann V Accavitti, Craig B. Thompson
Abstract: Methods for re-establishing normal sleep patterns in adults with age-related sleep disorders are provided. In particular, methods are disclosed wherein a compound that stimulates growth hormone and/or prolactin secretion is orally administered to subjects just prior to retiring.
Abstract: The present invention relates to the interaction of Rad51 and Xrcc3 to form a complex that mediates DNA repair in eukaryotic cells. A functional Rad51/Xrcc3 complex can be introduced into a cell to increase the resistance of the cell to DNA damaging agents. The invention also provides for a clinical application of a regimen combining Rad51 and Xrcc3 to reduce the side effects of radiotherapy and chemotherapy in a patient. In addition, the invention discloses methods for identifying candidate substances that interact with the Rad51/Xrcc3 complex. In another embodiment of the invention, preventing the formation of the Rad51/Xrcc3 complex increases the susceptibility of a cell to DNA damaging agents. This strategy can be used in combination with a DNA damaging agent or factor to kill cancerous cells.
Type:
Application
Filed:
April 26, 2001
Publication date:
November 1, 2001
Applicant:
ARCH Development Corporation.
Inventors:
Ralph R. Weichselbaum, Douglas K. Bishop
Abstract: The present invention provides isolated and purified polynucleotides that encode plant and cyanobacterial polypeptides that participate in the carboxylation of acetyl-CoA. Isolated cyanobacterial and plant polypeptides that catalyze acetyl-CoA carboxylation are also provided. Processes for altering acetyl-CoA carboxylation, increasing herbicide resistance of plants and identifying herbicide resistant variants of acetyl-CoA carboxylase are also provided.
Abstract: The present invention provides isolated and purified polynucleotides that encode plant polypeptides that participate in the carboxylation of acetyl-CoA. Also provided are methods for identifying such nucleic acid segments and polypeptides. Processes for altering acetyl-CoA carboxylation, increasing herbicide resistance of plants and identifying herbicide resistant variants of acetyl-CoA carboxylase are also provided.
Abstract: The invention relates generally to compositions of and methods for obtaining and using a polypeptide other than BCL-2 that affects programmed vertebrate cell death. The invention relates as well to polynucleotides encoding those polypeptides, recombinant vectors carrying those sequences, the recombinant host cells including either the sequences or vectors, and recombinant polypeptides. The invention further provides methods for using the isolated, recombinant polypeptides in assays designed to select and improve substances capable of altering programmed cell death for use in diagnostic, drug design and therapeutic applications.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
October 16, 2001
Assignees:
Arch Development Corporation, The Regent of the University of Michigan
Inventors:
Craig B. Thompson, Lawrence H. Boise, Gabriel Nuñez
Abstract: The present invention provides 8-substituted O6-benzylguanine, 4(6)-substituted 2-amino-5-nitro-6(4)-benzyloxypyrimidine, and 4(6)-substituted 2-amino-5-nitroso-6(4)-benzyloxypyrimidine derivatives which have been found to be effective AGT inactivators, as well as pharmaceutical compositions comprising such derivatives along with a pharmaceutically acceptable carrier. The present invention further provides a method of enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent which causes cytotoxic lesions at the O6-position of quanine, by administering to a mammal an effective amount of one of the aforesaid derivatives, 2,4-diamino-6-benzyloxy-s-triazine, 5-substituted 2,4-diamino-6-benzyloxypyrimidines, or 8-aza-O6-benzylguanine, and administering to the mammal an effective amount of an antineoplastic alkylating agent which causes cytotoxic lesions at the O6-position of guanine.
Type:
Grant
Filed:
June 9, 2000
Date of Patent:
October 16, 2001
Assignees:
The United States of America as represented by the Department
of Health and Human Services, The Penn State Research Foundation, Arch Development Corporation
Inventors:
Robert C. Moschel, Anthony E. Pegg, M. Eileen Dolan, Mi-Young Chae
Abstract: The present invention relates to the use of adenovirus-mediated gene transfer to regulate function in cardiac and vascular smooth muscle cells. A recombinant adenovirus comprising a DNA sequence that codes for a gene product is delivered to a cardiac or vascular smooth muscle cell and the cell is maintained until that gene product is expressed. Delivery is direct injection into a muscle cell or infusing a pharmaceutical composition containing an adenovirus virus vector construct intravascularly.
Abstract: Disclosed is a smooth muscle cell specific promoter, the SM22&agr; gene promoter as well as the murine cDNA and genomic SM22&agr; nucleic acid sequences. Also disclosed are methods of preventing restenosis following balloon angioplasty and methods of treating asthma based on inhibition of smooth muscle cell proliferation by expressing cell cycle control genes, or contraction inhibiting peptides in smooth muscle cells, under the control of the SM22&agr; promoter.
Abstract: Disclosed is a smooth muscle cell specific promoter, the SM22&agr; gene promoter as well as the murine cDNA and genomic SM22&agr; nucleic acid sequences. Also disclosed are methods of preventing restenosis following balloon angioplasty and methods of treating asthma based on inhibition of smooth muscle cell proliferation by expressing cell cycle control genes, or contraction inhibiting peptides in smooth muscle cells, under the control of the SM22&agr; promoter.
Abstract: Disclosed is a smooth muscle cell specific promoter, the SM22&agr; gene promoter as well as the murine cDNA and genomic SM22&agr; nucleic acid sequences. Also disclosed are methods of preventing restenosis following balloon angioplasty and methods of treating asthma based on inhibition of smooth muscle cell proliferation by expressing cell cycle control genes, or contraction inhibiting peptides in smooth muscle cells, under the control of the SM22&agr; promoter.
Abstract: A method, system and computer readable medium for the computerized assessment of breast cancer risk, wherein a digital image of a breast is obtained and at least one feature, and typically plural features, are extracted from a region of interest in the digital. The extracted features are compared with a predetermined model associating patterns of the extracted features with a risk estimate derived from corresponding feature patterns associated with a predetermined model based on gene carrier information or clinical information, or both gene carrier information and clinical information, and a risk classification index is output as a result of the comparison.
Abstract: A method, system, and computer product for the automated segmentation of the lung fields and costophrenic angle (CP) regions in posteroanterior (PA) chest radiographs wherein image segmentation based on gray-level threshold analysis is performed by applying an iterative global gray-level thresholding method to a chest image based on the features of a global gray-level histogram. Features of the regions in a binary image constructed at each iteration are identified and analyzed to exclude regions external to the lung fields. The initial lung contours that result from this global process are used to facilitate a local gray-level thresholding method. Individual regions-of-interest (ROIs) are placed along the initial contour. A procedure is implemented to determine the gray-level thresholds to be applied to the pixels within the individual ROIs. The result is a binary image, from which final contours are constructed. Smoothing processes are applied, including a unique adaptation of a rolling ball method.
Type:
Grant
Filed:
February 23, 1998
Date of Patent:
August 28, 2001
Assignee:
Arch Development Corporation
Inventors:
Samuel G. Armato, III, Maryellen L. Giger, Heber MacMahon
Abstract: A method and apparatus are provided for reconstructing a set of CT images from helical CT data. The method includes the steps of receiving the helical CT data and generating a set of fan-beam sinograms at equally spaced longitudinal positions. The method further includes the steps of estimating a set of parallel-beam sinograms from the generated set of fan-beam sinograms and reconstructing the CT images using a parallel beam reconstruction algorithm.
Abstract: The present invention relates to the synthesis of chiral cis-aziridines (IIIa and IIIb) by reacting an imine (I) with a diazo compound (II) in the presence of a chiral vaulted biary-Lewis Acid complex as shown below:
Abstract: A method, system and computer readable medium configured for computerized detection of lung abnormalities, including obtaining a standard digital chest image and a soft-tissue digital chest image; generating a first difference image from the standard digital chest image and a second difference image from the soft-tissue digital chest image; identifying candidate abnormalities in the first and second difference images; extracting from the standard digital chest image and the first difference image predetermined first features of each of the candidate abnormalities identified in the first difference image; extracting from the soft-tissue digital chest image and the second difference images predetermined second features of each of the candidate abnormalities identified in the second difference image; analyzing the extracted first features and the extracted second features to identify and eliminate false positive candidate abnormalities respectively corresponding thereto; applying extracted features from remainin
Abstract: The present invention features a human Nkx-2.2 polypeptide and nucleotide sequences encoding Nkx-2.2 polypeptides. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:1. In addition, the invention features polynucleotide sequences that hybridize under stringent conditions to SEQ ID NO:1. In related aspects the invention features expression vectors and host cells comprising polynucleotides that encode a human Nkx-2.2 polypeptide. The present invention also relates to antibodies that bind specifically to a human Nkx-2.2 polypeptide, and methods for producing human Nkx-2.2 polypeptides.
Type:
Grant
Filed:
January 20, 1998
Date of Patent:
May 29, 2001
Assignees:
The Regents of the University of California, Arch Development Corp.
Inventors:
Michael S. German, Graeme I. Bell, Hiroto Furuta, Lori Sussel
Abstract: A method and system for monitoring at least one of a system, a process and a data source. A method and system have been developed for carrying out surveillance, testing and modification of an ongoing process or other source of data, such as a spectroscopic examination. A signal from the system under surveillance is collected and compared with a reference signal, a frequency domain transformation carried out for the system signal and reference signal, a frequency domain difference function established. The process is then repeated until a full range of data is accumulated over the time domain and a SPRT sequential probability ratio test methodology applied to determine a three-dimensional surface plot characteristic of the operating state of the system under surveillance.
Type:
Grant
Filed:
November 14, 1997
Date of Patent:
May 29, 2001
Assignee:
Arch Development Corporation
Inventors:
Kenneth C. Gross, Stephan W. Wegerich, Cynthia Criss-Puszkiewicz, Alan D. Wilks
Abstract: The present invention relates generally to the field of diabetes. More particularly, it concerns the identification of genes responsible for NIDDM1 for use in diagnostic and therapeutic applications. The present invention demonstrates that the NIDDM1 locus is, in fact, the calpain 10 gene. The invention further relates to the discovery that analysis of mutations in calpain genes and gene products can be diagnostic for type 2 diabetes. The invention also contemplates methods of treating diabetes in view of the fact that calpain mutations can cause diabetes. Further, the invention relates to novel polynucleotides of the NIDDM1 locus and polypeptides encoded by such polynucleotides.
Type:
Grant
Filed:
October 21, 1999
Date of Patent:
May 22, 2001
Assignees:
ARCH Development Corporation & Board of Regents, The University of Texas System
Inventors:
Yukio Horikawa, Naohisa Oda, Craig L. Hanis, Graeme I. Bell, Nancy J. Cox
Abstract: A cross-linked water-insoluble ion exchange resin comprised of polymerized monomers having a phenyl ring is disclosed. A contemplated resin contains (i) polymerized phenyl ring-containing monomers having a phosphonic acid ligand linked to the phenyl ring, (ii) about 2 to about 5 millimoles per gram (mmol/g) of phosphorus as phosphonic acid ligands, and (iii) a sufficient amount of a sulfonic acid ligand such that the ratio of mmol/g of phosphonic acid to mmol/g sulfonic acid is up to 3:1. A process for removing polyvalent metal cations from aqueous solution, and a process for removing iron(III) cations from acidic copper(II) cation-containing solutions that utilize the contemplated resin or other resins are disclosed.
Type:
Grant
Filed:
December 28, 1998
Date of Patent:
May 15, 2001
Assignee:
Arch Development Corporation
Inventors:
Spiro Alexandratos, Christopher A. Shelley, E. Philip Horwitz, Renato Chiarizia